These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
727 related articles for article (PubMed ID: 20873251)
1. [Use of inhaled tobramycin in patients with cystic fibrosis]. Chermenskiĭ AG; Gembitskaia TE Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251 [TBL] [Abstract][Full Text] [Related]
2. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641 [TBL] [Abstract][Full Text] [Related]
3. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404 [TBL] [Abstract][Full Text] [Related]
4. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations. Al-Aloul M; Nazareth D; Walshaw M J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814 [TBL] [Abstract][Full Text] [Related]
5. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222 [TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542 [TBL] [Abstract][Full Text] [Related]
8. Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis. Berlana D; Llop JM; Manresa F; Jódar R Pharmacotherapy; 2011 Feb; 31(2):146-57. PubMed ID: 21275493 [TBL] [Abstract][Full Text] [Related]
9. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647 [TBL] [Abstract][Full Text] [Related]
10. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Parkins MD; Elborn JS Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231 [TBL] [Abstract][Full Text] [Related]
11. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282 [TBL] [Abstract][Full Text] [Related]
12. Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project. Coates AL; Green M; Leung K; Chan J; Ribeiro N; Louca E; Ratjen F; Charron M; Tservistas M; Keller M Pediatr Pulmonol; 2008 Aug; 43(8):753-9. PubMed ID: 18613006 [TBL] [Abstract][Full Text] [Related]